ViewsML

📍 Vancouver, Canada🗓 Founded 2022👥 16 employees💰 Last funded Jan 2026
Biotechnology Research🌐 viewsml.com
Website LinkedIn
ViewsML is building the worlds first virtual biomarker library using AI to generate per-cell spatial insights from routine pathology images without the need for physical immunohistochemistry (IHC). By virtualizing IHC, a diagnostic process that has remained unchanged for decades, ViewsML enables scientists and clinicians to generate biomarker staining results in minutes rather than the days to weeks required by conventional methods. The company’s platform analyzes standard H&E pathology slides to predict biomarker spatial expression at the individual cell level while preserving precious tissue samples and integrating into existing workflows. The result is faster biomarker discovery, accelerated clinical trials, and earlier insights that can guide treatment decisions for patients. Working with leading pharmaceutical companies, diagnostic labs, and healthcare systems, ViewsML is helping unlock the full biological value of existing pathology data and enabling a faster, more scalable path to precision medicine. To learn more, visit www.viewsml.com.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in ViewsML?
ViewsML has 1 investors on record on gritt.io, 1 mid-stage.
When did ViewsML last raise funding?
The most recent investment in ViewsML recorded on gritt.io was in January 2026.
When was ViewsML founded?
ViewsML was founded in 2022.
What industry is ViewsML in?
ViewsML operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ViewsML based?
ViewsML is headquartered in Vancouver, Canada.